Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

被引：3
作者：
Schmidt, Andrew [1 ]
Azad, Arun [2 ]
Goh, Jeffrey [3 ,4 ]
Harris, Carole [5 ,6 ]
Joshua, Anthony M. [7 ]
Weickhardt, Andrew [8 ]
Krieger, Laurence [9 ]
机构：
[1] Liz Plummer Canc Ctr, Cairns, Qld, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Butterfield St, Herston, Qld, Australia
[4] Univ Queensland, St Lucia, Qld, Australia
[5] St George Hosp, Kogarah, NSW, Australia
[6] Sutherland Clin Sch UNSW, Kogarah, NSW, Australia
[7] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[9] Royal North Shore Hosp, Northern Canc Inst, Reserve Rd, St Leonards, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors; INTERFERON-ALPHA; PREEXISTING AUTOIMMUNE; OPEN-LABEL; EVEROLIMUS; SUNITINIB; EFFICACY; SURVIVAL; CANCER; NEPHRECTOMY; LENVATINIB;
D O I：
10.1111/ajco.13289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
引用
收藏
页码：3 / 10
页数：8
相关论文
共 50 条
  • [21] Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Nishihara, Kiyoaki
    Ogasawara, Naoyuki
    Kurose, Hirofumi
    Hayashi, Shuichiro
    Chikui, Katsuaki
    Suyama, Shunsuke
    Nakiri, Makoto
    Matsuo, Mitsunori
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2015, 35 (06) : 3415 - 3421
  • [22] Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
    Tanaka, Nobuyuki
    Mizuno, Ryuichi
    Shirotake, Suguru
    Ito, Keiichi
    Yasumizu, Yota
    Masunaga, Ayako
    Ito, Yujiro
    Miyazaki, Yasumasa
    Hagiwara, Masayuki
    Kanao, Kent
    Mikami, Shuji
    Nakagawa, Ken
    Momma, Tetsuo
    Masuda, Takeshi
    Asano, Tomohiko
    Oyama, Masafumi
    Oya, Mototsugu
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (07) : 293.e17 - 293.e25
  • [23] Sequential therapy and new therapy options for metastatic renal cell carcinoma
    Hornig, M.
    Gruenwald, V.
    ONKOLOGE, 2015, 21 (01): : 43 - +
  • [24] Sequential therapy and new therapy options for metastatic renal cell carcinoma
    Hornig, M.
    Gruenwald, V.
    ONKOLOGE, 2015, 21 (01): : 43 - +
  • [25] Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review
    Petrelli, Fausto
    Vavassori, Ivano
    Rossitto, Mauro
    Dottorini, Lorenzo
    CANCERS, 2024, 16 (14)
  • [26] First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis
    Rousseau, Benoit
    Kempf, Emmanuelle
    Desamericq, Gaelle
    Boissier, Emilie
    Chaubet-Houdu, Marie
    Joly, Charlotte
    Saldana, Carolina
    Boussion, Helene
    Neuzillet, Cindy
    Macquin-Mavier, Isabelle
    Oudard, Stephane
    Salomon, Laurent
    de la Taille, Alexandre
    Tournigand, Christophe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 107 : 44 - 53
  • [27] Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma-Analysis Using Diagnostic Nodes
    Rothermundt, Christian
    Bailey, Alexandra
    Cerbone, Linda
    Eisen, Tim
    Escudier, Bernard
    Gillessen, Silke
    Gruenwald, Viktor
    Larkin, James
    McDermott, David
    Oldenburg, Jan
    Porta, Camillo
    Rini, Brian
    Schmidinger, Manuela
    Sternberg, Cora
    Putora, Paul M.
    ONCOLOGIST, 2015, 20 (09) : 1028 - 1035
  • [28] Defining risk status in the first-line treatment of metastatic renal cell carcinoma
    Schmidinger, Manuela
    Zielinski, Christoph C.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) : 961 - 968
  • [29] Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    Yu-Wei Chen
    Brian I. Rini
    Current Oncology Reports, 2022, 24 : 695 - 702
  • [30] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
12345